DSNKY Stock Performance, Insider Transaction and News

DSNKY - DAIICHI SANKYO COMPANY LIMITED

Market Cap	57.05B	P/E	74.35	EPS this Y	-	Ern Qtrly Grth	134.40%
Income	186.05B	Forward P/E	-	EPS next Y	-	50D Avg Chg	-6.00%
Sales	1.5T	PEG	-	EPS past 5Y	-	200D Avg Chg	-9.00%
Dividend	98.00%	Price/Book	0.04	EPS next 5Y	-	52W High Chg	-21.00%
Recommedations	-	Quick Ratio	2.79	Shares Outstanding	1.92B	52W Low Chg	19.00%
Insider Own	-	ROA	3.74%	Shares Float	1.89B	Beta	0.29
Inst Own	0.02%	ROE	12.43%	Shares Shorted/Prior	-/-	Price	29.74
Gross Margin	72.28%	Profit Margin	12.38%	Avg. Volume	250,850	Target Price	-
Oper. Margin	22.26%	Earnings Date	-	Volume	88,171	Change	-3.03%

Healthcare | Drug Manufacturers - General | Japan

About DAIICHI SANKYO COMPANY LIMITED

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

DAIICHI SANKYO COMPANY LIMITED News

04/11/24	Atossa (ATOS) Reports Positive Results From EVANGELINE Study
04/08/24	Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
04/08/24	AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
04/08/24	AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
04/05/24	ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
04/04/24	Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug
04/03/24	REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
04/02/24	AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance
04/02/24	Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
03/04/24	Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer
02/28/24	Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues
02/19/24	Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
02/16/24	Daiichi invests 1 bln eur near Munich to make precision cancer drugs
02/01/24	Q4 2023 Merck & Co Inc Earnings Call
01/29/24	AstraZeneca, Daiichi aim for first pan-tumor ADC approval
01/29/24	ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors
01/17/24	U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen
01/08/24	Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
01/04/24	Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo
01/03/24	Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation

DSNKY Chatroom

DonCorleone77 Posted - 2 weeks ago

$AZN $DSNKY 2 of 2 - ENHERTU approved for treatment of unresectable or metastatic HER2 positive ....The first tumor agnostic approval of a HER2 directed therapy and ADC was based on efficacy data in 192 adult patients with previously treated unresectable or metastatic HER2 positive solid tumors who were enrolled in one of three multicenter phase 2 trials from the DESTINY clinical development program, including DESTINY-PanTumor02, DESTINY-Lung01 or DESTINY-CRC02. The major efficacy outcome measure in all three of the studies was confirmed ORR and an additional efficacy outcome measure was DOR. ENHERTU is approved with Boxed WARNINGS for interstitial lung disease/pneumonitis and Embryo-Fetal toxicity.

DonCorleone77 Posted - 2 weeks ago

$AZN $DSNKY 1 of 2 - ENHERTU approved for treatment of unresectable or metastatic HER2 positive Daiichi Sankyo (DSNKY) and AstraZeneca's (AZN) ENHERTU has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ENHERTU is a specifically engineered HER2 directed antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca....

NEWBIGTECH Posted - 1 month ago

$ESPR Maybe call the company , and $DSNKY TO keep everyone in the loop. I am sure they would want to also know why the stock is manipulated, or at least seems to be.

NEWBIGTECH Posted - 1 month ago

$ESPR $DSNKY , I agree, management with ESPR are not doing everything possible to bring the stock price up, or protect the company. I have called and left messages with the company to no avail. That is why I also add the SEC in all correspondence.

NEWBIGTECH Posted - 1 month ago

$ESPR GSA Capital Partners LLP Has $1.09 Million Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) A number of analysts have issued reports on ESPR shares. HC Wainwright cut their price objective on shares of Esperion Therapeutics from $22.00 to $16.00 and set a "buy" rating for the company in a report . $PFE $JNJ #AMGN $DSNKY

YoloAlfred Posted - 2 months ago

$ESPR add $DSNKY to your watchlist

YoloAlfred Posted - 01/31/24

$ESPR I had ticker $DSNKY added this morning. .....put it on your watchlist (our partner in EU)

YoloAlfred Posted - 01/31/24

$DSNKY

YoloAlfred Posted - 01/31/24

$DSNKY OK ESPR CLUB.....add this to your watchlist to follow our partner in Europe